"Owing to its favorable molecular imaging characteristics and extended half-life, 18F-flurpiridaz is poised to become a valuable agent for cardiac stress PET imaging, offering clinicians a robust tool for the evaluation of CAD." The guideline includes information on clinical indications, contraindications, and considerations for 18F-flurpiridaz PET. It addresses qualifications and responsibilities of personnel performing cardiac stress testing using 18F-flurpiridaz, protocol (and potential protocol modifications), biodistribution and dosimetry, and the 18F-flurpiridaz PET workflow. "This document is designed to promote high-quality, safe, and effective nuclear medicine practice in the evaluation of CAD," emphasized the authors. SNMMI, ASNC, EANM, and ACNM periodically define new procedure standards/practice guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to deliver effective and safe medical care to patients.